PT -期刊文章盟梅兰妮Metral盟伊莎贝拉AU -彼得brgger盟右路放倒Klemens Gutbrod Nadin盟盟-乌苏拉Kunze盟Isaure -马克·维尼斯盟Riccardo Pignatti AU - Matthias Cavassini盟Renaud Du Pasquier TI -神经认知障碍的患病率在成功和衰老瑞士HIV-COHORT (P2.301) DP - 2017年4月18日TA -神经病学PG - P2.301 VI - 88 IP - 16补充4099 - //www.ez-admanager.com/content/88/16_Supplement/P2.301.short 4100 - //www.ez-admanager.com/content/8首页8/16_Supplement/P2.301.full所以Neurology2017 4月18日;88 AB -目的:本研究旨在确定神经认知障碍的患病率和发病率(非传染性疾病)通过纵向评估在4年时间内大量成功和衰老艾滋病的队列。背景:感染艾滋病毒相关的神经认知障碍的患病率(手)和混杂因素在成功老龄化的贡献是未知的。结果给出了基线的里程碑。设计/方法:这是一个持续的,前瞻性纵向、多中心、多语言(德语、法语和意大利语)研究在瑞士艾滋病队列研究被称为NAMACO研究(神经认知老化评估代谢和队列)。到目前为止,我们已经分析了899名感染艾滋病病毒的受试者年龄超过45年经历彻底的标准化的神经心理学评估受一开始研究。诊断的手,我们称为Frascati标准。结果:我们的队列(平均年龄55岁,80%为男性,92%的白人)有高比例的检测不到病毒载量(96%,VL< 50拷贝/毫升;当前的CD4细胞632 / mm3和中值值最低点CD4细胞180 / mm3)。在基线,非传染性疾病的患病率是41%,27%的病人患有手(26%的无症状的神经认知障碍(ANI), 0.7%的轻度神经认知障碍,和0.7%艾滋病痴呆),14%的人由于其他因素(主要是精神疾病)。较低的就业状况(36%)的患病率更高ANI(31%)和“其他”(25%)。 Motor skills (42%), speed of processing (33%) and attention/working memory (33%) were the most frequently impaired domains.Conclusions: We were able to implement a standardized neuropsychological testing in 3 national languages, which provides a unique comprehensive view of the cognitive status of older HIV-infected patients in Switzerland. Despite the fact that 96% of our cohort was aviremic, the prevalence of HAND remains high, mostly characterized by ANI. Psychiatric disorders represent the most important confounding factor. Motor skills, speed of processing and attention/working memory were the most impaired domains.Disclosure: Dr. Métral has nothing to disclose. Dr. Locatelli has nothing to disclose. Dr. Brugger has nothing to disclose. Dr. Gutbrod has nothing to disclose. Dr. Kunze has nothing to disclose. Dr. Nadin has nothing to disclose. Dr. Schwind has nothing to disclose. Dr. Pignatti has nothing to disclose. Dr. Cavassini has received research support from Merck Sharp & Dohme Ltd., and Gilead. Dr. Du Pasquier has received personal compensation for activities with Biogen, Novartis, Abbott, ViiV, EMD Serono, and Merck Sharp & Dohme Ltd.